UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: September 8, 2017
(Date of earliest event reported)
CELLECTAR
BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 1-36598 | 04-3321804 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
3301 Agriculture Drive, Madison, Wisconsin
53716
(Address of principal executive offices)
(608) 441-8120
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| ITEM 7.01 | REGULATION FD DISCLOSURE |
On September 8, 2017, the University of Wisconsin School of Medicine and Health issued a press release announcing that the University of Wisconsin Carbone Cancer Center published a study in the Journal of Nuclear Medicine finding that Cellectar Biosciences, Inc.’s lead compound, CLR 131, could become the first targeted, molecular radiotherapy to be tested in clinical trials that treats a broad variety of solid tumors in children. The press release can be found at the following URL address: http://www.med.wisc.edu/news-events/clr-131-found-to-broadly-target-pediatric-solid-tumors/51323.
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: September 13, 2017 | CELLECTAR BIOSCIENCES, INC. | |||||
| By: | /s/ John P. Hamill | |||||
| Name: | John P. Hamill | |||||
| Title: | Interim Chief Financial Officer | |||||
| 3 |